The slower pace of getting gene therapies to patients will most likely require the development of new standards and means of production. (Photo: Getty)
Despite the enormous promise of gene therapies, challenges in producing those therapies may put them out of reach of most American consumers at least in the near future, a new report said.
The report by the PWC Health Research Institute (HRI), outlines a myriad of challenges for gene therapies. Such therapies often are modified for single patients, raising questions of the scalability of the treatments. Rapid production is difficult—but patients are often facing life-threatening diseases and may not have much time. Supply chains and availability are limited: the report notes that only five ZIP codes in the country have health systems that offer all four gene therapies that currently have FDA approval.
Recommended For You
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
